Stereotaxis Inc

Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stereotaxis anticipates revenue growth in 2023 with key innovations

Stereotaxis is poised for growth with key innovations nearing commercialization and a strong balance sheet.
Strategic collaborations, improved pipeline visibility, and targeted growth strategies position the company for future success.
Challenges in customer engagement and market penetration require proactive strategies to drive revenue growth.
Opportunities in SaaS business spin-off, IDN engagement, and product launches offer avenues for revenue expansion and market presence.

Stereotaxis Inc reports revenue decline but expects growth opportunities

Stereotaxis Inc reports revenue decline but expects growth with Genesis
Positive feedback on technology, regulatory progress, and innovation efforts
Challenges include catheter shortages and financial balancing act
Opportunities lie in increasing system orders and upcoming market releases

Stereotaxis Inc reports robust revenue growth and strategic collaborations

Stereotaxis Inc's Q2 2023 performance showcased strong revenue growth and strategic collaborations driving innovation.
While facing challenges like regulatory delays and cash flow issues, the company is focused on reducing cash usage and advancing key projects.
Opportunities lie in connectivity software releases, product development, and regulatory submissions, positioning Stereotaxis for future growth.

Stereotaxis reports Q3 revenue growth, faces operational challenges

Stereotaxis Inc saw modest revenue growth in Q3 driven by robotic system sales, but faced an operating loss.
Maintaining a strong financial position with no debt provides stability amidst operational challenges.
The company's focus on innovation and market strategies presents opportunities for future growth and product development.

Stereotaxis Inc reports Q4 revenue of $4.6M, focuses on innovation and regulatory progress

Stereotaxis Inc navigated challenges in Q4 2023 with a focus on innovation and strategic transformation. Strong financial position and confidence in regulatory processes position the company well for future growth. Revenue guidance for 2024 indicates potential for stable recurring revenue and increased system revenue.

Stereotaxis reports Q1 revenue growth, innovation progress, and APT acquisition

Stereotaxis Inc's Q1 2024 earnings call highlighted revenue growth, innovation progress, and the acquisition of APT. Despite challenges with recurring revenue and an operating loss, the company is optimistic about future growth driven by system backlog and new orders.

Stereotaxis Inc. reports Q2 loss, anticipates growth from GenesisX shipments

Stereotaxis Inc. faces challenges from reduced capital revenue but shows resilience with stable recurring revenue and a strong gross margin.
The company's strategic initiatives, including GenesisX and the APT acquisition, position it well for future growth and market expansion.
Analysts' inquiries reflect interest in key growth drivers like GenesisX, manufacturing scale-up, and macroeconomic influences on the business.
Overall, Stereotaxis Inc. aims for a stronger second half in 2024, leveraging new product offerings and revenue streams for improved financial performance.

Stereotaxis Inc reports revenue growth in Q3 2024 earnings

Stereotaxis Inc showed solid revenue growth in Q3 2024, driven by system and recurring revenue.
While facing challenges in operating expenses and profitability, the company has opportunities for growth.
Managing expenses and capitalizing on revenue potential could position Stereotaxis for improved financial performance.
The increase in cash reserves also provides a buffer for future investments and operations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ST. LOUIS, May 13, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2024.

Stereotaxis Reports 2024 First Quarter Financial Results

ST. LOUIS, May 13, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has entered into a definitive share purchase agreement under which Stereotaxis will acquire Access Point Technologies EP (APT), a privately-held Minnesota-based developer of innovative electrophysiology catheters.

Stereotaxis Announces Definitive Agreement to Acquire Access Point Technologies

ST. LOUIS, April 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 first quarter on Monday, May 13, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m.

Stereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024

Augmedix

Lucid Diagnostics

Let's just get something straight off the bat – penny stocks to rebound are risky. They're incredibly treacherous in terms of both short-term downside and longer-term damage to your portfolio.

3 Penny Stocks That Could Make a Big Comeback by the End of Q2

American Resources Corp

Braemar Hotels & Resorts Inc

Creative Realities Inc

Pioneer Power Solutions

Penny stocks could be your ticket to striking it rich. But don't expect easy money!

7 Penny Stocks That Could 5X by the End of 2024

Brainsway

Crescent Point Energy

Genius Sports

TransAlta

Taboola

TScan Therapeutics

Generally speaking, you want to minimize your exposure to cheap stocks under $10. Yes, smaller companies have the potential to rise dramatically higher than their larger counterparts.

Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With

The Magic catheter human trial was successful. All 20 patients had acute success and there were 0 adverse events. Stereotaxis submitted the Magic catheter to EU and US regulators, with expectations of CE Mark approval in May or June.

Major Regulatory Approvals Coming For Stereotaxis In The Next 10 Months

Stereotaxis (STXS) announces the regulatory submissions of its MAGiC catheter in Europe and the United States, which are intended for use in minimally invasive cardiac ablation treatments.

Stereotaxis (STXS) Seeks Clearance for MAGiC Catheter

Stereotaxis, Inc. (NYSE:STXS ) Q4 2023 Earnings Conference Call March 4, 2024 4:30 PM ET Company Participants David Fischel - Chairman and CEO Kimberly Peery - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Jason Wittes - ROTH MKM Alex Nowak - Craig-Hallum Adam Maeder - Piper Sandler Operator Good afternoon. Thank you for joining us for Stereotaxis' Fourth Quarter and Full Year 2023 Earnings Conference Call.

Stereotaxis, Inc. (STXS) Q4 2023 Earnings Call Transcript

ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that regulatory submissions were made recently in both Europe and the United States for the MAGiC™ catheter. These submissions follow successful initial clinical results in an ongoing trial.

Stereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States

ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Stereotaxis Reports 2023 Full Year Financial Results

ST. LOUIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the first treatment of patients with a newly launched Genesis Robotic Magnetic Navigation (RMN) system at Intermountain Medical Center, flagship hospital of Intermountain Health, based in Salt Lake City. Intermountain Medical Center is the leading provider of robotic heart rhythm care in Utah and the Intermountain Region.

Intermountain Health Extends Leadership in Heart Care with Adoption of Advanced Robotic Technology

ST. LOUIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 fourth quarter and full year ended December 31, 2023 on Monday, March 4, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments.

Stereotaxis to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

ST. LOUIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that the first patients have been successfully treated using its Magnetic Interventional Ablation Catheter, MAGiC™. Stereotaxis' MAGiC catheter is a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures.

Stereotaxis Announces First Patients Successfully Treated Using MAGiC Ablation Catheter

LEXINGTON, Ky. and ST. LOUIS, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, and Baptist Health Lexington, a leading health provider in Kentucky, today announced that physicians have built upon their two-decades of leadership in robotic heart care with the successful treatment of first patients using the newest advancement in the technology, the Genesis Robotic Magnetic Navigation (RMN) System.

Baptist Health Lexington Enhances 20-Year Leadership in Pioneering Advanced Robotic Technology for Heart Disease Patients

ST. LOUIS, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Piper Sandler 35th Annual Healthcare Conference. Mr. Fischel will present on Stereotaxis' business and technology during a Fireside Discussion on Thursday, November 30, 2023, at 1:30 pm ET.

Stereotaxis to Participate in Piper Sandler 35th Annual Healthcare Conference

Stereotaxis was forced to do a human trial for its Magic catheter before it can get CE Mark. This is starting in a few weeks. Stereotaxis will soon submit a PMA for FDA approval of the Magic catheter 180 days after submission. China is set to approve Genesis in Q1 of next year.

Imminent Magic Catheter Approval Will Spike Stereotaxis Stock

Stereotaxis, Inc. (STXS) Q3 2023 Earnings Call Transcript

ST. LOUIS, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2023.

Stereotaxis Reports 2023 Third Quarter Financial Results

ST. LOUIS, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the United States have been treated successfully utilizing Abbott's EnSite™ X EP System integrated with Stereotaxis' Robotic Magnetic Navigation System. The integration of Abbott's leading cardiac mapping system and Stereotaxis' advanced robotic technology, first announced at Heart Rhythm 2023, combines highly detailed real-time diagnostic information with the unprecedented precision and stability of robotics during therapy delivery.

Abbott and Stereotaxis Technologies Used in First Integrated Procedures in the United States

ST. LOUIS, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 third quarter on Thursday, November 9, 2023 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Company's results and corporate developments.

Stereotaxis to Report Third Quarter 2023 Financial Results on November 9, 2023

ST. LOUIS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation's 7th Annual Meeting, which will take place October 19-20 in Washington, DC.

Stereotaxis Robotic Technology to be Featured during 7th Annual Meeting of the Society for Cardiac Robotic Navigation

ST. LOUIS, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at Heart Centre Rigshospitalet of Copenhagen University Hospital successfully treated the first patients using Stereotaxis' Genesis Robotic Magnetic Navigation System. The Genesis system is the latest and most advanced robotic technology available for the treatment of heart rhythm disorders. Rigshospitalet is among the first in Europe, and the only hospital in Denmark, to offer the Genesis system to patients.

Heart Centre Rigshospitalet Enhances Leadership in Patient Care with Adoption of Latest Robotic Technology

ST. LOUIS, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at Overland Park Regional Medical Center (OPRMC) launched and successfully completed the first procedures using the advanced Genesis Robotic Magnetic Navigation (RMN) System.

Overland Park Regional Medical Center Becomes First U.S. Hospital with Two Stereotaxis Robotic Systems for Arrhythmia Treatment

ST. LOUIS, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its technology will be the focus of multiple live long-distance telerobotic procedures at the upcoming Asia Pacific Heart Rhythm Society (APHRS) Scientific Sessions.

News for Stereotaxis Inc Stock (STXS)